Where is ipsen in blanchardstown industrial park

You can get to Ipsen Manufacturing Ireland Ltd. Moovit helps you find alternative routes or times. Get directions from and directions to Ipsen Manufacturing Ireland Ltd. We make riding to Ipsen Manufacturing Ireland Ltd. Skip to main content. How to get to Ipsen Manufacturing Ireland Ltd.

See Ipsen Manufacturing Ireland Ltd. Get directions now. Directions to Ipsen Manufacturing Ireland Ltd. Blanchardstown with public transportation The following transit lines have routes that pass near Ipsen Manufacturing Ireland Ltd. The company's current directors have been the director of 0 other Irish companies between them. Ipsen Manufacturing Ireland Limited has 1 shareholder. Generate a B2B Marketing List with ease and grow your business. Identify key decision makers and pre-qualified new prospects for your sales and business development teams.

Similar Companies - Create a marketing list of similar companies. Vision-net Credit Scores save your business the time and cost of chasing slow payers. Evaluate risk at client application stage or run continuous credit checks on your full customer base. Satisfy due diligence requirments on Ipsen Manufacturing Ireland Limited in one single 'time-saving' search. Background check Companies, Sole Traders or Individuals and minimise your spend with more efficient Anti-Money Laundering checks and reports.

Read More ». Located in Paris and Washington, Dominique led many company-wide transformation projects across Europe, US and Africa, working hand in hand with management and their teams.

She supported clients to set their strategic priorities at corporate, business unit, and therapeutic area level, and she worked with a number of brand teams to accelerate brand performance.

She brings a truly cross-functional perspective, having worked closely with most functions in pharmaceutical companies. In parallel, she initiated the creation of a community of women executives in France, focused on developing the capabilities of women executives on key business topics such as innovation, leadership in transformation, business model disruption.

Through a career of more than 20 years in the pharmaceutical industry, Stewart has deep experience leading country and global commercial functions in oncology and specialty care markets, including Canada, Switzerland, and the United States.

Prior to joining Ipsen, Steven held leadership roles in science-based bioethics and built an innovative digital health startup in cancer care after serving for five years as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety at Merck. Steven is board certified in internal medicine and cardiology with broad clinical training across internal medicine including medical oncology, gastroenterology, rheumatology and pulmonary oncology at university hospitals in Munich, Germany.

Throughout his career, he has engaged in part-time clinical practice, late-stage pharmaceutical research and medical teaching. Steven received his M. Dominique is the president of ETHICS, an association which includes international professionals in Ethics and Compliance working in the healthcare sector. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer.

He has an extensive track record of creating successful business development deals in multiple therapeutic areas in Europe, Asia and North America. Howard Mayer, M. Howard obtained his B. Aidan Murphy, Ph. He holds a Ph. Mari brings 20 years of healthcare leadership experience, from across the pharmaceutical industry, having worked in the US, Europe and in Japan.

She joined Ipsen from Novartis where she had held both global strategy and country operational roles in Japan and in the UK. In addition to her focus in oncology, Mari has worked in other specialty care environments such as ophthalmology, neuroscience, and immunology. In her role, Gwenan is responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen.

She brings 30 years of experience in pharmaceuticals at global, regional and country roles. Over the course of her career, she has held a variety of leadership roles of in public affairs, corporate, science and product communications, patient advocacy and marketing at AbbVie, GSK and Schering-Plough.

It ensures that the company has reliable procedures for identifying, measuring and monitoring its commitments and risks, as well as adequate financial and operational internal controls. Marc de Garidel started his career with the group Eli Lilly and pursued at Amgen, from to , with increasing responsibility positions in the US and Europe. Previously, he was Director of several biotechnology companies, including Vice-Chairman of the Board of Directors of Vifor Pharma Switzerland between May and formerly Galenica , of which he was member of the Board since The Board of Directors has set up six permanent committees and has defined both the composition and powers of these committees.

The Nomination Committee is comprised of a minimum of three directors and a maximum of six directors, including at least one-third of independent directors, chosen from among Directors who are not executive officers.

It meets at least twice a year. The Ethics and Governance Committee is comprised of a minimum of three directors and a maximum of six directors, including at least one independent director. The Compensation Committee is comprised of a minimum of three directors and a maximum of six directors, half being independent directors, chosen from among Directors who are not executive officers. The Audit Committee is comprised of a minimum of three Directors and a maximum of six Directors at the most, including two-thirds of independent Directors, chosen from among Directors who are not executive officers.

The Audit Committee meets at least four times a year. The Innovation and Development Committee is comprised of the Chairman of the Board and four other permanent members of the Board of Directors. It meets at least four times a year. August Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders.

December Ipsen announces new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients.

Exelixis, Inc. Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics. You are now leaving the Ipsen Group website. To continue, please click on « Continue ». You are now leaving the Ipsen Group section.